{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:07:50Z","timestamp":1653736070971},"reference-count":47,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2020,3,25]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Huntington's disease is characterized by three side effects, including motor\ndisturbances, psychiatric elements, and intellectual weakness. The onset for HD has nonlinear converse\nassociations with the number of repeat sequences of the polyglutamine mutations, so that younger patients\nhave a tendency for longer repeats length. This HD variation is because of the development of a\npolyglutamine (CAG) repeats in the exon 1 of the Huntingtin protein.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> In the present study, a few derivatives utilized as a part of the treatment of HD, are used to\ncreate the pharmacophore model and based on the features of the pharmacophore model; an attempt is\nmade to design the de-novo drug for the HD protein. HD protein structure was built and docked with\nthe novel ligand, based on shared feature pharmacophore model, through a ligand-based pharmacophore\nmodeling approach.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The novel ligand contains 1 HBAs, 2 HBDs, and 2 aromatic rings. It fulfills all the properties of certain\ndrug-likeness rules, non-toxic in nature. In the docked complex, the common interactive amino acids\nidentified are SER 1035, ALA 1062, MET 1068, LEU 1031, and THR 1036, which confirmed the validity\nand stability of a ligand molecule to be used as a drug in the treatment of Huntington\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A novel ligand can be used in clinical trials as a drug molecule against the mutations of\nHD gene and in laboratory procedures for efficacy analysis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573409915666181207104437","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T10:51:42Z","timestamp":1544179902000},"page":"134-144","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["De-Novo Ligand Design against Mutated Huntington Gene by Ligand-based Pharmacophore Modeling Approach"],"prefix":"10.2174","volume":"16","author":[{"given":"Anum","family":"Munir","sequence":"first","affiliation":[{"name":"Department of Bioinformatics and Biosciences, Faculty of Health and Life Sciences, Capital University of Science and Technology, Islamabad, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaukat I.","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Biosciences, Faculty of Health and Life Sciences, Capital University of Science and Technology, Islamabad, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A.","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Mechanical Engineering (SMME), National University of Science and Technology, Islamabad, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"Roos R.A.","year":"2010","unstructured":"Roos R.A.; Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 2010,5,40","journal-title":"Orphanet J Rare Dis"},{"key":"ref=2","first-page":"6, pp. 298-378","author":"Bruyn G.W.","year":"1968","unstructured":"Bruyn G.W.; untington\u2019s chorea: historical, clinical and laboratory\nsynopsis. In:. Handbook of Clinical Neurology Elsevier: Amsterdam1968,6, pp. 298-378","journal-title":"Handbook of Clinical Neurology"},{"key":"ref=3","author":"Zoghbi H.Y.","year":"2014","unstructured":"Zoghbi H.Y.; Orr H.T.; Patterson M.C.; Firth H.V.; Deputy D.C.H.; Dashe J.F.; Huntington disease: Genetics and pathogenesis 2014"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","volume":"71","author":"Paulsen J.S.","year":"2001","unstructured":"Paulsen J.S.; Ready R.E.; Hamilton J.M.; Mega M.S.; Cummings J.L.; Neuropsychiatric aspects of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 2001,71(3),310-314","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1176\/ajp.140.6.728","volume":"140","author":"Caine E.D.","year":"1983","unstructured":"Caine E.D.; Shoulson I.; Psychiatric syndromes in Huntington\u2019s disease. Am J Psychiatry 1983,140(6),728-733","journal-title":"Am J Psychiatry"},{"key":"ref=6","author":"Cummings J.L.","year":"1995","unstructured":"Cummings J.L.;  In: Behavioral Neurology of movements disorders 1995","journal-title":"In: Behavioral Neurology of movements disorders"},{"key":"ref=7","first-page":"193","volume":"1","author":"Folstein S.E.","year":"1983","unstructured":"Folstein S.E.; Folstein M.F.; Psychiatric features of Huntington\u2019s disease: recent approaches and findings. Psychiatr Dev 1983,1(2),193-205","journal-title":"Psychiatr Dev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1600-0447.1994.tb01587.x","volume":"90","author":"Shiwach R.","year":"1994","unstructured":"Shiwach R.; Psychopathology in Huntington\u2019s disease patients. Acta Psychiatr Scand 1994,90(4),241-246","journal-title":"Acta Psychiatr Scand"},{"key":"ref=9","first-page":"22, pp.\n81-126","author":"Morris M.","year":"1991","unstructured":"Morris M.; Psychiatric aspects of Huntington's disease: In Harper\nPS, ed. Huntington\u2019s disease. WB Saunders: London 1991,22, pp.\n81-126"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"Paulsen J.S.","year":"2008","unstructured":"Paulsen J.S.; Langbehn D.R.; Stout J.C.; Aylward E.; Ross C.A.; Nance M.; Guttman M.; Johnson S.; MacDonald M.; Beglinger L.J.; Duff K.; Kayson E.; Biglan K.; Shoulson I.; Oakes D.; Hayden M.; Predict-HD investigators and coordinators of the huntington study group. detection of huntington\u2019s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008,79(8),874-880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/0959-4388(95)80072-7","volume":"5","author":"Gusella J.F.","year":"1995","unstructured":"Gusella J.F.; MacDonald M.E.; Huntington\u2019s disease: CAG genetics expands neurobiology. Curr Opin Neurobiol 1995,5(5),656-662","journal-title":"Curr Opin Neurobiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev.ne.19.030196.000455","volume":"19","author":"Paulson H.L.","year":"1996","unstructured":"Paulson H.L.; Fischbeck K.H.; Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 1996,19,79-107","journal-title":"Annu Rev Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"Evans S.J.","year":"2013","unstructured":"Evans S.J.; Douglas I.; Rawlins M.D.; Wexler N.S.; Tabrizi S.J.; Smeeth L.; Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 2013,84(10),1156-1160","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-050710-134457","volume":"63","author":"Wexler N.S.","year":"2012","unstructured":"Wexler N.S.; Huntington\u2019s disease: advocacy driving science. Annu Rev Med 2012,63,1-22","journal-title":"Annu Rev Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","volume":"1","author":"Myers R.H.","year":"2004","unstructured":"Myers R.H.; Huntington\u2019s disease genetics. NeuroRx 2004,1(2),255-262","journal-title":"NeuroRx"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","volume":"361","author":"Bates G.","year":"2003","unstructured":"Bates G.; Huntingtin aggregation and toxicity in Huntington\u2019s disease. Lancet 2003,361(9369),1642-1644","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"Gusella J.F.","year":"1983","unstructured":"Gusella J.F.; Wexler N.S.; Conneally P.M.; Naylor S.L.; Anderson M.A.; Tanzi R.E.; Watkins P.C.; Ottina K.; Wallace M.R.; Sakaguchi A.Y.; A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature 1983,306(5940),234-238","journal-title":"Nature"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","year":"1993","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell The Huntington\u2019s Disease Collaborative Research Group1993,72(6),971-983","journal-title":"Cell"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"Duyao M.","year":"1993","unstructured":"Duyao M.; Ambrose C.; Myers R.; Novelletto A.; Persichetti F.; Frontali M.; Folstein S.; Ross C.; Franz M.; Abbott M.; Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat Genet 1993,4(4),387-392","journal-title":"Nat Genet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"Frank S.","year":"2014","unstructured":"Frank S.; Treatment of Huntington\u2019s disease. Neurotherapeutics 2014,11(1),153-160","journal-title":"Neurotherapeutics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1155\/2013\/705373","volume":"26","author":"Pidgeon C.","year":"2013","unstructured":"Pidgeon C.; Rickards H.; The pathophysiology and pharmacological treatment of Huntington disease. Behav Neurol 2013,26(4),245-253","journal-title":"Behav Neurol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"Armstrong M.J.","year":"2012","unstructured":"Armstrong M.J.; Miyasaki J.M.; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012,79(6),597-603","journal-title":"Neurology"},{"key":"ref=23","first-page":"545","volume":"3","author":"Paleacu D.","year":"2007","unstructured":"Paleacu D.; Tetrabenazine in the treatment of Huntington\u2019s disease. Neuropsychiatr Dis Treat 2007,3(5),545-551","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/0006-2952(83)90388-X","volume":"32","author":"Bagchi S.P.","year":"1983","unstructured":"Bagchi S.P.; Differential interactions of phencyclidine with tetrabenazine and reserpine affecting intraneuronal dopamine. Biochem Pharmacol 1983,32(19),2851-2856","journal-title":"Biochem Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2174\/138161206777698693","volume":"12","author":"Bonelli R.M.","year":"2006","unstructured":"Bonelli R.M.; Wenning G.K.; Pharmacological management of Huntington\u2019s disease: an evidence-based review. Curr Pharm Des 2006,12(21),2701-2720","journal-title":"Curr Pharm Des"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.2147\/JRLCR.S46843","volume":"81","author":"Voet A.","year":"2014","unstructured":"Voet A.; Qing X.; Lee X.Y.; De Raeymaecker J.; Tame J.; Zhang K.; De Maeyer M.; Pharmacophore modeling: advances, limitations, and current utility in drug discovery. J Receptor Ligand Channel Res 2014,81","journal-title":"J Receptor Ligand Channel Res"},{"key":"ref=27","first-page":"313","volume":"9","author":"Geppert T.D.","year":"1989","unstructured":"Geppert T.D.; Lipsky P.E.; Antigen presentation at the inflammatory site. Crit Rev Immunol 1989,9(4),313-362","journal-title":"Crit Rev Immunol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/bioinformatics\/14.8.656","volume":"14","author":"Rebhan M.","year":"1998","unstructured":"Rebhan M.; Chalifa-Caspi V.; Prilusky J.; Lancet D.; GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics 1998,14(8),656-664","journal-title":"Bioinformatics"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"D225","DOI":"10.1093\/nar\/gkq1189","volume":"39","author":"Marchler-Bauer A.","year":"2011","unstructured":"Marchler-Bauer A.; Lu S.; Anderson J.B.; Chitsaz F.; Derbyshire M.K.; DeWeese-Scott C.; Fong J.H.; Geer L.Y.; Geer R.C.; Gonzales N.R.; Gwadz M.; Hurwitz D.I.; Jackson J.D.; Ke Z.; Lanczycki C.J.; Lu F.; Marchler G.H.; Mullokandov M.; Omelchenko M.V.; Robertson C.L.; Song J.S.; Thanki N.; Yamashita R.A.; Zhang D.; Zhang N.; Zheng C.; Bryant S.H.; CDD: a Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res 2011,39(Database issue),D225-D229","journal-title":"Nucleic Acids Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"W407-10","DOI":"10.1093\/nar\/gkm290","volume":"35","author":"Wiederstein M.","year":"2007","unstructured":"Wiederstein M.; Sippl M.J.; ProSA-web: interactive web service\nfor the recognition of errors in three-dimensional structures of proteins.. Nucleic Acids Res 2007,35(Web Server issue),W407-10","journal-title":"Nucleic Acids Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.1853201","volume":"253","author":"Bowie J.U.","year":"1991","unstructured":"Bowie J.U.; L\u00fcthy R.; Eisenberg D.; A method to identify protein sequences that fold into a known three-dimensional structure. Science 1991,253(5016),164-170","journal-title":"Science"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/pro.5560020916","volume":"2","author":"Colovos C.","year":"1993","unstructured":"Colovos C.; Yeates T.O.; Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 1993,2(9),1511-1519","journal-title":"Protein Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/j.1476-5381.1993.tb13737.x","volume":"109","author":"Lazareno S.","year":"1993","unstructured":"Lazareno S.; Birdsall N.J.; Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 1993,109(4),1110-1119","journal-title":"Br J Pharmacol"},{"key":"ref=34","author":"Wolber G.","unstructured":"Wolber G.; Langer T.; LigandScout: Automated Pharmacophore\nModel Creation"},{"key":"ref=35","author":"Pollastri M.P.","year":"2001","unstructured":"Pollastri M.P.;  Overview of the Rule of FiveCurrent Protocols in Pharmacology 2001","journal-title":"Overview of the Rule of FiveCurrent Protocols in Pharmacology"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.4172\/2169-0138.1000141","volume":"06","author":"Munir A.","year":"2017","unstructured":"Munir A.; Azam S.; Ali S.; Mehmood A.; Hussain Shah A.; Khan M.S.; Fazal S.; Repurposing of Modified Alpidem and Propoxyphene to Cure AURKA, BCAS1, GNAS and MLH1 Gene Mutations in Colorectal Cancer. Drug Designing: Open Access 2017,06(01)","journal-title":"Drug Designing: Open Access"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/157340607780059521","volume":"3","author":"Khedkar S.A.","year":"2007","unstructured":"Khedkar S.A.; Malde A.K.; Coutinho E.C.; Srivastava S.; Pharmacophore modeling in drug discovery and development: an overview. Med Chem 2007,3(2),187-197","journal-title":"Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/812148","volume":"2014812148","author":"Kandakatla N.","year":"2014","unstructured":"Kandakatla N.; Ramakrishnan G.; Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors. Adv Bioinforma 2014,2014812148","journal-title":"Adv Bioinforma"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.4172\/2169-0138.1000137","volume":"05","author":"Munir A.","year":"2016","unstructured":"Munir A.; Azam S.; Mehmood A.; Structure-Based Pharmacophore Modeling, Virtual Screening and Molecular docking for the Treatment of ESR1 Mutations in Breast Cancer. Drug Designing: Open Access 2016,05(03)","journal-title":"Drug Designing: Open Access"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"Yang S.Y.","year":"2010","unstructured":"Yang S.Y.; Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010,15(11-12),444-450","journal-title":"Drug Discov Today"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/cc9800071","volume":"1","author":"Ghose A.K.","year":"1999","unstructured":"Ghose A.K.; Viswanadhan V.N.; Wendoloski J.J.; A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999,1(1),55-68","journal-title":"J Comb Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2615-23","DOI":"10.1021\/jm020017n","volume":"6,45","author":"Veber DF.","year":"2002","unstructured":"Veber DF.; Johnson SR.; Cheng HY.; Smith BR.; Ward KW.; Kopple KD.; Molecular properties that influence the oral bioavailability\nof drug candidates. J Med Chem 2002,6,45(12),2615-23","journal-title":"J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1021\/jm000292e","volume":"43","author":"Egan W.J.","year":"2000","unstructured":"Egan W.J.; Merz K.M.; Baldwin J.J.; Prediction of drug absorption using multivariate statistics. J Med Chem 2000,43(21),3867-3877","journal-title":"J Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1021\/jm015507e","volume":"44","author":"Muegge I.","year":"2001","unstructured":"Muegge I.; Heald S.L.; Brittelli D.; Simple selection criteria for drug-like chemical matter. J Med Chem 2001,44(12),1841-1846","journal-title":"J Med Chem"},{"key":"ref=45","author":"Datta D.","year":"2003","unstructured":"Datta D.; Protein-ligand interactions: docking, design and protein\nconformational change California Institute of Technology 2003","journal-title":"California Institute of Technology"},{"key":"ref=46","volume":"21","author":"Haseeb M.","year":"2014","unstructured":"Haseeb M.; Vaqar S.; Fazal S.; Khalil A.; Ligand based pharmacophore development for colorectal cancer drugs. Prof Med J 2014,21(5)","journal-title":"Prof Med J"},{"key":"ref=47","first-page":"1","author":"Datta D.","year":"2003","unstructured":"Datta D.;  Protein-ligand interactions: Docking, design and protein conformational change 2003,1-53","journal-title":"Protein-ligand interactions: Docking, design and protein conformational change"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/168149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T03:21:11Z","timestamp":1586834471000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/168149\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409915666181207104437","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}